Literature DB >> 32835606

1-Deoxysphingolipids cause autophagosome and lysosome accumulation and trigger NLRP3 inflammasome activation.

Mario A Lauterbach1, Victor Saavedra2, Matthew S J Mangan1,3, Anke Penno2, Christoph Thiele2, Eicke Latz1,3,4, Lars Kuerschner2.   

Abstract

1-Deoxysphingolipids (deoxySLs) are atypical sphingolipids of clinical relevance as they are elevated in plasma of patients suffering from hereditary sensory and autonomic neuropathy (HSAN1) or type 2 diabetes. Their neurotoxicity is described best but they inflict damage to various cell types by an uncertain pathomechanism. Using mouse embryonic fibroblasts and an alkyne analog of 1-deoxysphinganine (doxSA), the metabolic precursor of all deoxySLs, we here study the impact of deoxySLs on macroautophagy/autophagy, the regulated degradation of dysfunctional or expendable cellular components. We find that deoxySLs induce autophagosome and lysosome accumulation indicative of an increase in autophagic flux. The autophagosomal machinery targets damaged mitochondria that have accumulated N-acylated doxSA metabolites, presumably deoxyceramide and deoxydihydroceramide, and show aberrant swelling and tubule formation. Autophagosomes and lysosomes also interact with cellular lipid aggregates and crystals that occur upon cellular uptake and N-acylation of monomeric doxSA. As crystals entering the lysophagosomal apparatus in phagocytes are known to trigger the NLRP3 inflammasome, we also treated macrophages with doxSA. We demonstrate the activation of the NLRP3 inflammasome by doxSLs, prompting the release of IL1B from primary macrophages. Taken together, our data establish an impact of doxSLs on autophagy and link doxSL pathophysiology to inflammation and the innate immune system.Abbreviations: alkyne-doxSA: (2S,3R)-2-aminooctadec-17yn-3-ol; alkyne-SA: (2S,3R)-2- aminooctadec-17yn-1,3-diol; aSA: alkyne-sphinganine; ASTM-BODIPY: azido-sulfo-tetramethyl-BODIPY; CerS: ceramide synthase; CMR: clonal macrophage reporter; deoxySLs: 1-deoxysphingolipids; dox(DH)Cer: 1-deoxydihydroceramide; doxCer: 1-deoxyceramide; doxSA: 1-deoxysphinganine; FB1: fumonisin B1; HSAN1: hereditary sensory and autonomic neuropathy type 1; LC3: MAP1LC3A and MAP1LC3B; LPS: lipopolysaccharide; MEF: mouse embryonal fibroblasts; MS: mass spectrometry; N3635P: azido-STAR635P; N3Cy3: azido-cyanine 3; N3picCy3: azido-picolylcyanine 3; NLRP3: NOD-like receptor pyrin domain containing protein 3; P4HB: prolyl 4-hydroxylase subunit beta; PINK1: PTEN induced putative kinase 1; PYCARD/ASC: PYD and CARD domain containing; SPTLC1: serine palmitoyltransferase long chain base subunit 1; SQSTM1: sequestosome 1; TLC: thin layer chromatography.

Entities:  

Keywords:  Autophagy; HSAN1; crystal; doxSA; innate immunity; lipid; macrophage

Mesh:

Substances:

Year:  2020        PMID: 32835606      PMCID: PMC8386713          DOI: 10.1080/15548627.2020.1804677

Source DB:  PubMed          Journal:  Autophagy        ISSN: 1554-8627            Impact factor:   16.016


  58 in total

1.  Multiplexed and single cell tracing of lipid metabolism.

Authors:  Christoph Thiele; Klaus Wunderling; Philipp Leyendecker
Journal:  Nat Methods       Date:  2019-10-14       Impact factor: 28.547

Review 2.  Multiple bonds for the lipid interest.

Authors:  Lars Kuerschner; Christoph Thiele
Journal:  Biochim Biophys Acta       Date:  2014-01-09

Review 3.  Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation.

Authors:  George S Abela
Journal:  J Clin Lipidol       Date:  2010-03-16       Impact factor: 4.766

4.  Localization of 1-deoxysphingolipids to mitochondria induces mitochondrial dysfunction.

Authors:  Irina Alecu; Andrea Tedeschi; Natascha Behler; Klaus Wunderling; Christian Lamberz; Mario A R Lauterbach; Anne Gaebler; Daniela Ernst; Paul P Van Veldhoven; Ashraf Al-Amoudi; Eicke Latz; Alaa Othman; Lars Kuerschner; Thorsten Hornemann; Frank Bradke; Christoph Thiele; Anke Penno
Journal:  J Lipid Res       Date:  2016-11-23       Impact factor: 5.922

5.  Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome?

Authors:  A Othman; M F Rütti; D Ernst; C H Saely; P Rein; H Drexel; C Porretta-Serapiglia; G Lauria; R Bianchi; A von Eckardstein; T Hornemann
Journal:  Diabetologia       Date:  2011-11-29       Impact factor: 10.122

Review 6.  Mammalian ceramide synthases.

Authors:  Michal Levy; Anthony H Futerman
Journal:  IUBMB Life       Date:  2010-05       Impact factor: 3.885

7.  Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release.

Authors:  Eivind O Samstad; Nathalie Niyonzima; Stig Nymo; Marie H Aune; Liv Ryan; Siril S Bakke; Knut T Lappegård; Ole-Lars Brekke; John D Lambris; Jan K Damås; Eicke Latz; Tom E Mollnes; Terje Espevik
Journal:  J Immunol       Date:  2014-02-19       Impact factor: 5.422

8.  Straightforward access to spisulosine and 4,5-dehydrospisulosine stereoisomers: probes for profiling ceramide synthase activities in intact cells.

Authors:  José Luis Abad; Ingrid Nieves; Pedro Rayo; Josefina Casas; Gemma Fabriàs; Antonio Delgado
Journal:  J Org Chem       Date:  2013-05-30       Impact factor: 4.354

9.  Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids.

Authors:  Anke Penno; Mary M Reilly; Henry Houlden; Matilde Laurá; Katharina Rentsch; Vera Niederkofler; Esther T Stoeckli; Garth Nicholson; Florian Eichler; Robert H Brown; Arnold von Eckardstein; Thorsten Hornemann
Journal:  J Biol Chem       Date:  2010-01-22       Impact factor: 5.157

10.  Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase. Formation of N-palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed fumonisin, AP1, and a new category of ceramide synthase inhibitor.

Authors:  H U Humpf; E M Schmelz; F I Meredith; H Vesper; T R Vales; E Wang; D S Menaldino; D C Liotta; A H Merrill
Journal:  J Biol Chem       Date:  1998-07-24       Impact factor: 5.157

View more
  5 in total

Review 1.  How location and cellular signaling combine to activate the NLRP3 inflammasome.

Authors:  Anil Akbal; Alesja Dernst; Marta Lovotti; Matthew S J Mangan; Róisín M McManus; Eicke Latz
Journal:  Cell Mol Immunol       Date:  2022-09-20       Impact factor: 22.096

Review 2.  Potential Mechanisms and Effects of Chinese Medicines in Treatment of Diabetic Atherosclerosis by Modulating NLRP3 Inflammasome: A Narrative Review.

Authors:  Jia-Yao Yuan; Yu Fu; Zhi-Hai Feng; Feng Sang; Ming-Yi Shao; Lei-Lei Li
Journal:  Chin J Integr Med       Date:  2022-05-04       Impact factor: 2.626

Review 3.  The Mechanism and Regulation of the NLRP3 Inflammasome during Fibrosis.

Authors:  Carol M Artlett
Journal:  Biomolecules       Date:  2022-04-26

Review 4.  An update on the regulatory mechanisms of NLRP3 inflammasome activation.

Authors:  Seungwha Paik; Jin Kyung Kim; Prashanta Silwal; Chihiro Sasakawa; Eun-Kyeong Jo
Journal:  Cell Mol Immunol       Date:  2021-04-13       Impact factor: 11.530

5.  1-Deoxysphingolipids, Early Predictors of Type 2 Diabetes, Compromise the Functionality of Skeletal Myoblasts.

Authors:  Duyen Tran; Stephen Myers; Courtney McGowan; Darren Henstridge; Rajaraman Eri; Sabrina Sonda; Vanni Caruso
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-24       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.